These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20498596)

  • 1. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
    Surrey ES
    Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
    Chwalisz K; Surrey E; Stanczyk FZ
    Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis.
    Akira S; Mine K; Kuwabara Y; Takeshita T
    Med Sci Monit; 2009 Jan; 15(1):CR1-4. PubMed ID: 19114964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose effects of progesterone in add-back therapy during GnRHa treatment.
    Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
    J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
    Surrey ES; Judd HL
    J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Add-back" therapy for endometriosis in adolescents.
    Lubianca JN; Gordon CM; Laufer MR
    J Reprod Med; 1998 Mar; 43(3):164-72. PubMed ID: 9564639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current approaches to optimizing the treatment of endometriosis in adolescents.
    Laufer MR
    Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
    Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
    J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [GnRH agonist and add back therapy--indications, results and problems in the treatment of genital endometriosis].
    Mettler L
    Zentralbl Gynakol; 2003; 125(7-8):267-75. PubMed ID: 14505262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis.
    DiVasta AD; Laufer MR
    Curr Opin Obstet Gynecol; 2013 Aug; 25(4):287-92. PubMed ID: 23770813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroidal and nonsteroidal "add-back" therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient.
    Surrey ES
    Fertil Steril; 1995 Oct; 64(4):673-85. PubMed ID: 7672133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
    Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
    Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis.
    Gallagher JS; Missmer SA; Hornstein MD; Laufer MR; Gordon CM; DiVasta AD
    J Pediatr Adolesc Gynecol; 2018 Aug; 31(4):376-381. PubMed ID: 29551430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for endometriosis.
    Fedele L; Berlanda N
    Expert Opin Emerg Drugs; 2004 May; 9(1):167-77. PubMed ID: 15155142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group.
    Surrey ES
    Fertil Steril; 1999 Mar; 71(3):420-4. PubMed ID: 10065775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of GnRH agonists plus add-back therapy in the treatment of endometriosis.
    Gargiulo AR; Hornstein MD
    Semin Reprod Endocrinol; 1997; 15(3):273-84. PubMed ID: 9383836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of add-back therapy in the United States.
    Olive DL
    Drugs Today (Barc); 2005 Jul; 41 Suppl A():23-6. PubMed ID: 16200222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone loss induced by GnRHa treatment in women].
    Matsuo H
    Nihon Rinsho; 2003 Feb; 61(2):314-8. PubMed ID: 12638227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose add-back therapy during postoperative GnRH agonist treatment.
    Tsai HW; Wang PH; Huang BS; Twu NF; Yen MS; Chen YJ
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):55-9. PubMed ID: 26927249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of bisphosphonate administration during Gn-RH agonist therapy for endometriosis].
    Aisaka K
    Nihon Rinsho; 2009 May; 67(5):1027-30. PubMed ID: 19432128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.